From www.bloodjournal.org by guest on September 11, 2016. For personal use only.

Plenary Paper TRANSPLANTATION

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event David M. Burns,1 Rose Tierney,1 Claire Shannon-Lowe,1 Jo Croudace,1 Charlotte Inman,1 Ben Abbotts,1 Sandeep Nagra,2 Christopher P. Fox,3 Sridhar Chaganti,2 Charles F. Craddock,2 Paul Moss,1 Alan B. Rickinson,1 Martin Rowe,1 and Andrew I. Bell1 1

School for Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; 2Centre for Clinical Haematology, University Hospitals Birmingham National Health Service Trust, Birmingham, United Kingdom; and 3Centre for Clinical Haematology, Nottingham University Hospitals National Health Service Trust, Nottingham, United Kingdom

Allogeneic stem cell transplantation (allo-HSCT) provides a unique opportunity to track Epstein-Barr virus (EBV) infection in the context of the reconstituting B-cell system. Although many allo-HSCT recipients maintain low or undetectable levels of EBV DNA • CD191CD271 memory posttransplant, a significant proportion exhibit elevated and rapidly increasing EBV loads B cells are detectable at which, if left untreated, may lead to potentially fatal EBV-associated posttransplant lymsupranormal frequencies in phoproliferative disease. Intriguingly, this high-level EBV reactivation typically arises in the patients with high-level EBV DNAemia following allogeneic first 31months posttransplant, at a time when the peripheral blood contains low numbers of CD27 memory cells which are the site of EBV persistence in healthy immunocompetent HSCT. donors. To investigate this apparent paradox, we prospectively monitored EBV levels and • These memory B cells are B-cell reconstitution in a cohort of allo-HSCT patients for up to 12 months posttransplant. In frequently positive for EBV patients with low or undetectable levels of EBV, the circulating B-cell pool consisted genomes and bear many of predominantly of transitional and naive cells, with a marked deficiency of CD271 memory the hallmarks of lymphoblastoid cells which lasted >12 months. However, among patients with high EBV loads, there was a transformation. significant increase in both the proportion and number of CD271 memory B cells. Analysis of sorted CD271 memory B cells from these patients revealed that this population was preferentially infected with EBV, expressed EBV latent transcripts associated with B-cell growth transformation, had a plasmablastic phenotype, and frequently expressed the proliferation marker Ki-67. These findings suggest that high-level EBV reactivation following allo-HSCT may drive the expansion of latently infected CD271 B lymphoblasts in the peripheral blood. (Blood. 2015;126(25):2665-2675)

Key Points

Introduction Epstein-Barr virus (EBV) is a widespread B-lymphotropic gammaherpesvirus with potent B-cell growth transforming activity. Following primary infection, the virus replicates in the oropharynx while establishing latency in a small number of infected memory B lymphocytes.1 In healthy individuals, this lifelong viral persistence is usually asymptomatic, as the proliferation of EBV-infected B cells is strictly controlled by host T-cell immunity.2 However, in immunocompromised individuals, EBV can drive the opportunistic outgrowth of virus-transformed B cells which may subsequently develop into lymphoproliferative lesions.3,4 For instance, patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), an intervention used to treat a wide range of hematologic conditions, remain profoundly T-cell compromised for many months posttransplant. Consequently a significant proportion of allo-HSCT patients develop high levels of circulating EBV DNA, referred to as EBV reactivation or DNAemia.5-11 These viral reactivations usually occur within the first few months posttransplant 11-17 and, if left untreated, can progress to life-

threatening posttransplant lymphoproliferative disease (PTLD). Accordingly, most transplant centers routinely monitor the levels of EBV DNA in the blood of allo-HSCT recipients for several months after transplant and preemptively administer rituximab, an antiCD20 monoclonal antibody, to those individuals who exhibit rapidly increasing viral loads. Although posttransplant monitoring has led to an improvement in the early detection of patients at risk of developing PTLD, the pathophysiology of EBV reactivation in the context of allo-HSCT remains poorly understood. Given that memory B cells are the normal reservoir of EBV persistence in immunocompetent individuals,18-20 we were particularly intrigued by existing reports in the literature that EBV reactivation following allo-HSCT usually occurs at a time when the newly reconstituting B-cell system consists predominantly of transitional and naive B cells.21-25 To investigate this apparent paradox, here we have explored the relationship between immune reconstitution and EBV reactivation in a cohort of allo-HSCT recipients and ask whether

Submitted August 19, 2015; accepted October 3, 2015. Prepublished online as Blood First Edition paper, October 8, 2015; DOI 10.1182/blood-2015-08665000.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

The online version of this article contains a data supplement. There is an Inside Blood Commentary on this article in this issue.

BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

© 2015 by The American Society of Hematology

2665

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. 2666

BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

BURNS et al

Table 1. Patient characteristics Age, y

Sex

Diagnosis

Donor

Regimen

Acute GVHD grade

Peak EBV, copies per mL*

PTLD

1

34

M

AML

MUD

Cy TBI C

II1

4.35 3 106

1

2

57

M

AML

MUD

FMC

II1

2.16 3 105

3

57

M

AML

MUD

FMC

I

1.60 3 105

4

55

M

AML

MUD

FMC

II1

3.31 3 104

5

64

M

MDS

MUD

FMC

II1

1.81 3 106

6

51

M

AML

MUD

FMC

I

1.41 3 105

7

61

M

AML

MUD

FMC

8

48

M

HL

MUD

FMC

II1

2.69 3 104

9

57

F

CLL

MUD

FMC

II1

1.54 3 106

10

57

M

AML

Sibling

FMC

I

9.49 3 104

11

67

F

MDS

MUD

FMC

12

61

M

AML

MUD

FMC

II1

5.36 3 105

13

50

F

AML

Sibling

FMC

I

2.50 3 105

14

55

M

AML

MUD

FMC

15

61

M

AML

MUD

FMC

16

65

M

AML

Sibling

FMC

17

51

F

ALL

Sibling

18

57

M

MDS

MUD

19

54

M

ALL

MUD

FMC

I

3.29 3 103

20

54

F

HL

Sibling

FMC

II1

4.24 3 103

21

58

M

T-PLL

Sibling

FMC

3.80 3 103

22

62

M

AML

MUD

FMC

1.34 3 103

23

64

M

AML

MUD

FMC

24

70

F

AML

MUD

FMC

25

66

M

AML

MUD

FMC

26

53

M

AML

Sibling

FMC

,5 3 102

27

61

M

MDS

Sibling

FMC

5.50 3 103

28

44

M

MF

MUD

FMC

,5 3 102

29

47

F

AML

MUD

FMC

Patient High EBV

1

9.73 3 104

1

1.67 3 106

No/low EBV 9.67 3 102 1.80 3 103 II1

3.20 3 103

FMC

I

3.65 3 103

FMC

I

,5 3 102

I

1.23 3 103 ,5 3 102

II1

I

1.37 3 103

,5 3 102

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; C, Campath; CLL, chronic lymphocytic leukemia; Cy, cyclophosphamide; F, female; FMC, fludarabine, melphalan, and Campath; HL, Hodgkin lymphoma; M, male; MDS, myelodysplastic syndrome; MF, myelofibrosis; MUD, matched unrelated donor; T-PLL, T-cell prolymphocytic leukemia; TBI, total body irradiation. *Clinical EBV load measured as EBV DNA copies per mL whole blood.

the well-documented pattern of immune reconstitution26-28 following allo-HSCT is perturbed in patients with high-level EBV reactivation. We have also characterized the phenotype of EBV-infected cells in patients with high-level EBV reactivation and ask whether, in this situation, EBV can colonize the numerically dominant transitional and naive B cells rather than memory B cells.

Patients, materials, and methods See supplemental Methods (available on the Blood Web site) for additional materials and methods. Patients and control donors Blood samples and clinical data were collected from patients undergoing T-cell–deplete allo-HSCT at University Hospital Birmingham (Birmingham, United Kingdom) between May 2009 and September 2012. Control blood samples were obtained from healthy laboratory donors. The study was approved by the National Research Ethics Service (REC references 05/Q2707/148 and 14/WM/0001) and participants gave written informed consent in accordance with the Declaration of Helsinki. All but 1 patient received reduced-intensity conditioning comprising fludarabine (30 mg/m2 daily for 5 days) and melphalan (140 mg/m2 for 1 day). A single patient received myeloablative conditioning comprising cyclophosphamide (60 mg/kg daily for 2 days) and total body irradiation (14.4 Gy in

8 fractions). All patients received a peripheral blood stem cell graft from either a human leukocyte antigen matched sibling or unrelated donor. For graft-versus-host disease (GVHD) prophylaxis, all patients received alemtuzumab (Campath) 10 mg daily IV for 5 days prior to transplant and ciclosporin; the patient who underwent myeloablative conditioning also received methotrexate (8 mg/m2 on alternate days for 4 days). All patients received aciclovir for a minimum of 3 months posttransplant. Recipient whole-blood samples were subjected to routine clinical monitoring of EBV DNA with testing performed every 1 to 2 weeks for the first 6 months posttransplant and intermittently thereafter (Health Protection Agency Laboratory, Heartlands Hospital, United Kingdom). Subsequently, 13 consecutive alloHSCT patients were identified with high-level EBV reactivation (defined as any EBV load over 2 3 104 genomes per mL; Table 1). These “high EBV” patients provided additional blood samples for research purposes at, or close to, the time of peak reactivation prior to starting preemptive rituximab treatment. Blood samples were also collected at around 3, 6, and 12 months posttransplant from a control “no/low EBV” group of 16 age- and sex-matched allo-HSCT patients with either undetectable or low-level EBV reactivation (defined as ,5000 EBV genomes per mL). Patient peripheral blood mononuclear cells (PBMCs) were isolated using density gradient centrifugation and cryopreserved for later analysis. Statistical analysis Statistical comparisons between the high EBV group at the time of reactivation (median, 109 days posttransplant; interquartile range [IQR], 92-141 days) and the no/low EBV group using combined data from the 3 and 6 months posttransplant samples (median, 112 days; IQR, 84-169 days) were made using the MannWhitney U test. GraphPad was used to perform statistical analyses and generate graphical plots.

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

EBV REACTIVATION FOLLOWING ALLO-HSCT

2667

Figure 1. Serial analysis of EBV loads in patients with high-level EBV reactivation. (A-M) Routine Q-PCR monitoring of whole-blood samples, collected every 1 to 2 weeks for at least 6 months following alloHSCT, was used to identify 13 patients with high-level EBV reactivation, defined as an EBV load .20 000 copies per mL blood. The dotted horizontal lines represent the limit of detection of the assay (500 EBV copies per mL); values below this were assigned a value of 250 copies per mL. The dashed vertical arrows indicate the time points at which samples were collected; the solid arrows indicate the time points of rituximab infusion. (E) Patient 5 died of PTLD, (F) patient 6 died of relapsed AML, and (I) patient 9 died of pneumonia (indicated by †).

Results Patient characteristics and kinetics of EBV reactivation

From routine clinical monitoring, we identified 13 allo-HSCT patients who developed high-level EBV reactivation during the first 6 months posttransplant (high EBV group) and 16 age- and sex-matched patients who either had undetectable or low viral loads at any time posttransplant (no/low EBV group). The clinical characteristics and viral loads of these 2 patient groups are summarized in Table 1. All 13 high EBV patients showed similar kinetics of reactivation (Figure 1), with a median interval from transplant to first EBV quantitative polymerase chain reaction (Q-PCR) positivity (.500 genomes per mL) of 99 days (IQR, 84-119 days). This was followed by a rapid expansion in circulating EBV DNA, with a median time from first Q-PCR positivity to high-level DNAemia of 7 days (IQR, 0-14 days) and a median peak viral load of 2.2 3 105 genomes per mL (Table 1). By contrast, 5 of 16 patients in the no/low EBV group remained Q-PCR–negative although

the others showed much lower viral burdens with a median peak load of 1.8 3 103 genomes per mL (Table 1). Because measurement of EBV DNA in whole blood does not distinguish between cellassociated EBV genomes or viral DNA in plasma, we also quantified the number of EBV genomes in PBMC DNA isolated from the high EBV group at the time of peak EBV reactivation and from the no/low EBV patients bled at around 3, 6, and 12 months posttransplant. Matching for time posttransplant, there was a highly significant increase in cell-associated EBV DNA from the high EBV cohort at peak reactivation (Figure 2). According to local clinical protocol, all patients with high-level EBV reactivation were preemptively treated with rituximab and assessed for possible PTLD. Patients 1, 5, and 10 were subsequently diagnosed with PTLD based on radiographic evidence of disease at 16, 9, and 1 day(s), respectively, after the onset of reactivation. Following rituximab infusion, 12 patients showed a complete response with lasting resolution of EBV DNAemia and disease where evident (Figure 1). Patient 5 died of progressive PTLD despite showing an initial reduction in EBV load following rituximab therapy (Figure 1).

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. 2668

BURNS et al

BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

observed a significant increase in both the proportion and number of CD271 B cells (Figure 4A-C; supplemental Figure 1). Notably, these expanded CD271 B-cell populations were almost entirely IgD2 , consistent with a class-switched memory B-cell phenotype (Figure 4A; supplemental Figure 1). Additional staining for surface k and l immunoglobulin light (IgL) chains revealed that the CD271 B cells from the majority of high EBV patients had a polytypic IgL phenotype, although 4 patients showed some evidence of light-chain restriction (supplemental Figure 3). De novo expansion of CD271 B cells is coincident with high-level EBV DNAemia

Figure 2. Cellular EBV loads in allo-HSCT patients. Cell-associated EBV loads were determined by Q-PCR screening of PBMC DNA from no/low EBV patients at around 3, 6, and 12 months posttransplant, and from high EBV patients at the time of peak EBV DNAemia. Viral loads from healthy control donors are included as a reference. The solid horizontal lines represent the medians of the positive values for each group. For the no/low EBV group, the median EBV loads from samples available at 3, 6, and 12 months posttransplant were 600, 1800, and 2700 EBV copies per 106 PBMCs, respectively. The median value for the high EBV group, collected at a median of 109 days posttransplant (IQR, 92-141 days), was 5.9 3 105 EBV copies per 106 PBMCs. Of the healthy controls with detectable EBV, the median viral load was 73 EBV copies per 106 PBMCs. For purposes of statistical analysis, comparison with the no/low EBV group was made with samples combined from the 3- and 6-month time points collected at a median of 112 days posttransplant (IQR, 84-169 days). EBV loads in the high EBV group were significantly higher than those of the no/low group (P , .0001). The dotted horizontal lines represent the limit of detection of the assay (10 EBV copies per 106 PBMCs) and samples with undetectable virus DNA were assigned a value of 1.

Reconstitution of main lymphocyte subsets

To characterize reconstitution of the main lymphocyte subsets following allo-HSCT, CD561CD32 natural killer (NK) cells, CD31 T cells, and CD191 B cells were identified by flow cytometry and quantified both as a proportion of total CD451 lymphocytes and as absolute numbers derived from the corresponding lymphocyte counts (Figure 3). The pattern of immune reconstitution among the no/low EBV patients at 3, 6, and 12 months posttransplant was in accord with earlier studies.26-28 Thus, there was marked numerical deficiency of all 3 lymphocyte subsets relative to healthy donors, with an initial predominance of NK cells that was gradually replaced by recovering T cells. Although the proportion of B cells in most no/low patients was normal (or supranormal) by 3 months posttransplant, the absolute number of B cells did not fully recover until 6 to 12 months (Figure 3). Matching for time posttransplant, a similar pattern was seen in the high EBV patients (Figure 3) indicating that high-level EBV reactivation did not significantly affect the reconstitution of the main lymphocyte subsets. High-level EBV reactivation is associated with increased numbers of CD271 B cells

The detailed immunophenotype of the emerging B cells posttransplant was then compared between the no/low EBV and high EBV cohorts. B-cell reconstitution in the no/low EBV group was characterized by an initial predominance of CD272IgD1 naive B cells, which lasted for .12 months posttransplant, and a marked delay in the recovery of CD271 memory B cells (Figure 4A-C; supplemental Figure 1). As expected, naive B cells in such patients showed a mostly transitional cell phenotype (CD38hiCD24hiCD101) that gradually declined over time (supplemental Figure 2).29 However, among the high EBV patients, we

We next asked whether the increased numbers of CD271 B cells observed in patients with high-level reactivation existed prior to the onset of EBV DNAemia. Immunophenotyping of PBMCs available from 6 high EBV patients collected a median of 32 days (16-73 days) prior to peak EBV reactivation revealed that these earlier samples contained both a significantly lower proportion and frequency of CD271 memory B cells (Figure 4D). Further analysis combining all available data from the high EBV patients at the time of reactivation and the no/low EBV patients at 3, 6, and 12 months posttransplant revealed no correlation between PBMC viral loads and the number of NK cells, T cells, or total B cells (supplemental Figure 4). However, there was a highly significant correlation between EBV load and the number of CD271 B cells, supporting the view that memory B cells are the site of EBV persistence following allo-HSCT. EBV selectively resides within the CD271 memory B-cell population

To obtain direct evidence that EBV is present in CD271 memory B cells following reactivation, PBMCs from 4 high EBV patients were sorted with a fluorescence-activated cell sorter (FACS) into CD191CD272 IgD1 naive B, CD191CD271 memory B, and CD192 non-B-cell subsets (supplemental Figure 5) and then assayed for EBV DNA using Q-PCR (Figure 5A). In all 4 cases, EBV was highly enriched in CD271 memory B cells but was almost absent from other lymphocyte populations. The extremely high viral loads seen in these memory B cells (median, 1.2 3 107 copies per 106 CD271 B cells) also suggested either there was a high frequency of EBV infection or EBV replication was occurring in a proportion of cells. To distinguish between these 2 possibilities, we estimated the fraction of infected cells by assaying for viral DNA in single cells isolated by FACS. We first validated our approach by sorting individual cells from mixtures containing known ratios of EBV-positive Kem Burkitt lymphoma cells and an isogenic EBV-negative derivative and then screening for the presence of EBV DNA by PCR. Using mixtures containing 25%, 50%, and 100% EBVpositive cells, we observed EBV DNA signals in 15 of 48 (31%), 23 of 48 (52%), and 39 of 48 (81%) wells, respectively, values which closely approximated the expected results. Applying the same technique to naive and memory B cells sorted by FACS from 4 high load patients, naive B cells were consistently EBV-negative but viral DNA was detected in a high proportion (81%-92%) of memory B cells in all 4 cases (Figure 5B). Notably, the median copy number of 19 EBV genomes per infected memory B-cell (IQR, 10-29) is consistent with viral latency and is in marked contrast to the much higher viral loads seen in productively infected B cells (median load, 2.4 3 104 EBV copies per cell) included here as a comparator (Lytic Akata, Figure 5C). In summary, the relatively low viral load and narrow distribution of viral genome copy number strongly suggest that high-level EBV reactivation following allo-HSCT is due to an accumulation of latently infected CD271 memory B cells.

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

EBV REACTIVATION FOLLOWING ALLO-HSCT

2669

Figure 3. Characterization of immune reconstitution of the main lymphocyte subsets following allo-HSCT. (A-F) Multicolor flow cytometry was used to enumerate CD561CD32 NK cells, CD31 T cells, and CD191 B cells in PBMC samples from allo-HSCT patients, either without (no/low EBV) or with (high EBV) high-level EBV reactivation, and from healthy controls. In each case, the left plot reports values as a percentage of CD451 lymphocytes; the right plot shows the values as absolute cell numbers per microliter of blood, based on the corresponding lymphocyte counts. The solid horizontal lines represent the median values for each group. No significant differences were seen for both the NK-cell and T-cell subsets between the no/low EBV group at 3 and 6 months posttransplant and the high EBV group at the time of peak reactivation. The proportion of B cells in the high EBV group was greater than in the no/low EBV group with borderline significance (P 5 .079), but there was a nonsignificant increase (P 5 .178) in absolute B-cell numbers.

CD271 memory B cells express EBV transcripts associated with growth transformation

EBV can adopt 1 of several forms of latent infection which can be distinguished by alternative patterns of virus gene expression and promoter usage.30 To characterize the viral gene expression profile in CD271 memory B cells from high EBV patients, we used Q-PCR to quantify EBV transcripts encoding the latent genes EBNA1, EBNA2, LMP1, and LMP2, the immediate early gene BZLF1, and the late lytic gene GP350/BLLF1; in addition, we also screened for transcripts initiated from 3 latent promoters, Wp, Cp, and Qp (Figure 6A). After normalizing the data to EBNA1 expression, all 3 patients tested showed readily detectable levels of Cp-initiated transcripts (with accompanying lower levels of Wp activity) and high levels of EBNA2 and LMP2 messenger RNA, whereas 2 cases also showed lymphoblastoid cell line (LCL)-like levels of LMP1 expression. This pattern of viral gene expression closely resembles the latency III pattern seen in an EBVtransformed B LCL (CD1Oku LCL; Figure 6B) but is clearly different to the more restricted latency I pattern seen in a representative Burkitt lymphoma cell line Rael-BL (Figure 6B). Expression of the lytic cycle transcripts BZLF1 and GP350 was much lower, ranging from 0.5% to 2% of the values seen in productively infected BL cells (Lytic Akata, Figure 6B). Overall, these results confirm that CD271 memory B cells

in allo-HSCT patients with high-level DNAemia predominantly harbor EBV as a latent infection and suggest that a proportion of infected cells express viral transcripts associated with B-cell growth transformation. CD271 memory B cells exhibit a proliferative phenotype

Given that CD271 memory B cells in patients with high-level EBV reactivation express viral genes that can drive B-cell proliferation, the final experiments sought to characterize the activation and proliferation status of these CD271 B cells in more detail. Flow cytometry revealed that a significant proportion of CD191CD271 B cells exhibited a CD242CD38hi plasmablastic immunophenotype (Figure 7A). Importantly, this CD242CD38hi population was significantly expanded in high EBV patients when compared with healthy controls (Figure 7B). We then compared the proliferation status of CD271 B cells from alloHSCT patients with healthy donor B cells by means of intracellular staining for Ki-67 expression. As expected, both naive and memory B cells from a healthy individual had a predominantly resting Ki-672 phenotype (Figure 7C), as did CD272IgD1 naive B cells from 3 high EBV patients (Figure 7D). By contrast, CD271 memory B cells from the same high EBV patients contained a substantial proportion (;50% in each case) of Ki-671 cells, indicative of cell proliferation (Figure 7C).

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. 2670

BURNS et al

BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

Figure 4. Alterations in B-cell subset frequencies between no/low EBV and high EBV patients following allo-HSCT. (A) Representative staining of PBMCs to identify CD27 2 IgD 1 naive, CD27 1 IgD 2 isotypeswitched memory, CD271 IgD1 nonswitched memory, and CD272 IgD2 B-cell populations in no/low EBV and high EBVallo-HSCT recipients, and in a healthy control. The no/low EBV patient was bled 98 days posttransplant when the EBV load was undetectable in whole blood. The high EBV patient was bled at 101 days posttransplant during high-level DNAemia (1.54 3 106 EBV copies per mL blood). (B) Enumeration of CD272IgD1 naive B cells expressed as a percentage of CD451 lymphocytes (left panel) or absolute numbers (right panel) in allo-HSCT patients and healthy controls. (C) Enumeration of CD271IgD2 memory B cells expressed as a percentage of CD451 lymphocytes (left panel) or absolute numbers (right panel) in allo-HSCT patients and healthy controls. In panels B and C, the solid horizontal lines represent the median values for each group. Both the percentage (P , .0001) and number (P , .0001) of memory B cells were significantly higher in the high EBV group compared with the no/low EBV group. (D) Enumeration of CD191CD271IgD2 memory B cells in PBMC samples prereactivation and at the point of highlevel EBV DNAemia. There was a significant increase in both the proportion (P , .004) and absolute number (P , .002) of memory B cells during high-level EBV reactivation.

Discussion Although EBV reactivation following allo-HSCT is an important clinical problem, it also provides a unique opportunity to study the biology of EBV infection in the context of newly emerging B- and T-cell systems. The present work was prompted by the apparent contradiction that EBV DNAemia usually occurs in the first few months posttransplant when there is a marked deficiency in circulating CD271 memory B cells, the natural reservoir for EBV in immunocompetent individuals. Here, we sought to explore the pattern of

immune reconstitution following allo-HSCT and, for the first time, characterize the detailed phenotype of EBV-infected cells in patients with high-level EBV reactivation. Notably, our approach differed from the previous studies in 2 important aspects. First, by prospectively monitoring EBV loads posttransplant, we were able to bleed patients at, or close to, their peak of EBV DNAemia. Second, we have compared the reconstitution of the main lymphocyte populations in patients with high-level reactivation (sampled at the time of peak viral load) and control patients with undetectable or low level EBV DNAemia. Importantly, among patients with high-level reactivation, we show that EBV maintains its selectivity for isotype-switched CD271 memory

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

Figure 5. EBV loads in different B-cell subsets in patients with high-level reactivation. (A) Cellular EBV loads determined by Q-PCR in bulk populations of unsorted total CD191 B cells and CD192 non-B cells sorted by FACS, CD272IgD1 naive B cells and CD271 memory B cells from 4 patients with high-level EBV reactivation. (B) Proportion of EBV-positive CD272IgD1 naive and CD271 memory B cells in the same 4 patients as above, determined by single-cell Q-PCR for EBV DNA. Gray shading represents the fraction of EBV-positive cells in the sorted naive and memory B-cell populations for each patient. (C) Distribution of EBV genome copy number per infected CD271 memory B cell. Values are only shown for EBVpositive cells, with the solid horizontal lines indicating the median value for each patient. As a comparator, we also determined the EBV genome copy number in EBVpositive AKBM Akata-GFP cells induced into lytic cycle (Lytic Akata). Following

EBV REACTIVATION FOLLOWING ALLO-HSCT

2671

B cells, but that high viral loads are associated with the early emergence of such cells. Several lines of evidence support the idea that this memory B-cell expansion is an EBV-driven event. Thus, further analysis of the CD27 1 B-cell population from high load patients revealed that the vast majority of cells are virus-positive, the population expresses viral genes associated with B-cell growth transformation, and a significant proportion express Ki-67 consistent with cell proliferation. The overall pattern of immune reconstitution following allo-HSCT has been well documented.26-28 In general, cells of the innate immune system including monocytes, macrophages, and NK cells are produced first and recover to normal frequencies within a few weeks posttransplant. By contrast, adaptive immunity returns much more slowly, with functional recovery of T and B lymphocytes taking up to 2 years.29,31 Immune reconstitution data from our no/low EBV patients sampled at 3, 6, and 12 months posttransplant are in accord with these previous studies. Intriguingly, our data suggest that the reconstitution of the major lymphocyte populations was not markedly different between this no/low EBV group and patients with high-level EBV reactivation, although we acknowledge that subtle differences in immune reconstitution may have been missed due to the relatively small cohort sizes. For example, future studies could explore the possibility that the numbers of EBV-specific CD81 T cells may be an informative marker to identify patients at risk of EBV reactivation.13,32-34 Notably, our data highlighted an important difference in B-cell reconstitution between the 2 transplant groups. The nascent B-cell system among the no/low EBV patients was dominated by transitional and naive cells for the first 6 to 12 months, in agreement with earlier studies,21-25,35 and consistent with the view that mature B cells reconstitute from newly engrafted donor stem cells. By contrast, high EBV patients showed a rapid increase in both the proportion and number of B cells expressing the memory marker CD27.36 This expansion consisted almost exclusively of IgG1 or IgA1 class-switched CD271 memory B cells, with few detectable IgD1CD271 nonswitched memory cells. Interestingly, not all patients sampled at the point of high-level EBV DNAemia had particularly raised levels of CD271 memory B cells. This variation may reflect the magnitude of reactivation because we observed a good correlation between cellular EBV loads and the absolute number of circulating CD271 memory B cells. Given these findings, we infer that the accumulation of isotypeswitched CD271 memory B cells in allo-HSCT patients is likely to result from de novo expansion associated with high-level EBV reactivation. This hypothesis is supported by our cell sorting data which indicated that EBV was almost exclusively present in the CD271 memory B cells in high load patients. Although a small fraction of EBV DNA (,1%) was detected within the naive B-cell and non-B-cell subsets, these results could be explained by low-level contamination with CD271 memory cells. Notably, a lack of sufficient numbers of CD271 B cells precluded a similar analysis of this population in the no/low EBV patients. In summary, although we had anticipated that EBV might be present in the numerically dominant transitional and naive B-cell populations in allo-HSCT recipients, the present data argue that EBV is restricted to CD271 memory B cells, just as in immunocompetent individuals.18,20 This is not to deny that EBV can

Figure 5 (continued) induction, cells that had entered virus lytic cycle were singlecell sorted on the basis of GFP expression before determining the genome load per cell by Q-PCR, as above. Although the majority of sorted GFP1 cells have in excess of 1000 EBV genomes per cell, note that a small proportion of GFP1 cells have much lower (latent) viral loads because viral replication is slightly delayed with respect to GFP expression. GFP, green fluorescent protein.

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. 2672

BURNS et al

BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

Figure 6. EBV gene expression in CD271 memory B cells in high load allo-HSCT patients. Absolute numbers of EBV transcripts were quantified using a Q-PCR array. All data were first normalized to cellular PGK1 expression and then expressed relative to the levels of EBNA1 transcript. (A) EBV gene expression in CD271 memory B cells sorted by FACS from patients 6, 9, and 12. (B) EBV gene expression in EBV-positive reference cell lines. CD1Oku LCL is a latently infected EBV-transformed B lymphoblastoid cell line characterized by activity of the Wp- and Cp promoters, and expression of EBNA1, EBNA2, LMP1, and LMP2 latent genes (a form of infection termed latency III). Rael-BL is a latently infected Burkitt lymphoma cell line which expresses a single latent gene EBNA1 transcribed from an alternative promoter Qp. Because both CD1Oku LCL and Rael-BL are tightly latent with only low-level expression of lytic cycle transcripts (exemplified by the immediate early gene BZLF1 and the late gene gp350), we also included a third reference line, AKBM Akata-GFP cells induced into lytic cycle by IgG crosslinking, to illustrate the much higher levels (typically .100-fold) of viral lytic gene transcription in productively infected cells.

also access other lymphocytes in certain situations, such as in T- and NK-cell lymphoproliferations.37 Indeed, a recent study by Calattini et al38 of patients with EBV-associated lymphoproliferation reported that .20% of the EBV-positive cells were phenotypically non-B, non-T, and nonmonocyte. The single-cell analysis of sorted naive and memory B cells from high load patients also provided valuable new insights into EBV reactivation following allo-HSCT. Remarkably, we estimated that 80% to 90% of the CD271 memory B cells were virus-positive, a frequency which is several orders of magnitude higher than the 1 in 5000 to 1 in 200 000 infected cells typically seen in healthy seropositive individuals.20,39,40 Moreover, we estimated that infected CD271 B cells typically carried 10 to 30 EBV genome copies. These values are consistent with viral loads found in latently infected EBV-positive cell lines41-43 and are also in accord with previous fluorescence in situ hybridization studies of allo-HSCT38 and solid organ transplant (SOT) patients.44 Crucially, we never found any cells with high EBV genome loads indicative of virus replication. Taken together, these observations indicate that high-level EBV DNAemia following allo-HSCT is fundamentally associated with an accumulation of latently infected B cells rather than due to EBV replication. Interestingly, the genome loads of individual infected B cells may also shed light on the proliferative

history of this population. Thus, a recent study, in which resting B cells were infected in vitro with EBV at ,1 virus particle per cell, found that the virus genome was amplified to around 20 to 40 copies per cell after 3 to 4 weeks in culture.42 We infer that the EBV-positive B cells in our high load transplant patients must have undergone multiple rounds of proliferation postinfection and therefore the initial infection event is likely to have occurred several weeks prior to the peak of reactivation. This hypothesis is consistent with our finding that numbers of CD271 memory B cells were much lower 2 to 3 weeks prior to the onset of reactivation. Further evidence that the accumulation of CD271 memory cells is an EBV-driven transformation event came from EBV gene expression profiling which detected several EBV latent transcripts associated with B-cell growth transformation45-47 Thus, our Q-PCR analysis revealed LCL-like levels of EBNA1, EBNA2, and LMP2 transcripts in all 3 patients tested, whereas 2 patients also had high levels of LMP1 expression. However, we cannot exclude the possibility of heterogeneity within the infected B-cell pool, and that 2 distinct populations of virus-positive memory B cells may simultaneously exist: 1 characterized by expression of the full spectrum of EBV latent genes (so called latency III) and the second characterized by a more restricted pattern of viral gene

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

Figure 7. Proliferation status of CD271 B cells in high load allo-HSCT patients. (A) Representative staining of PBMCs from a high EBV patient and a healthy control donor to identify CD38hi plasmablasts within the CD191CD271 memory B-cell population. (B) Proportion of CD191CD271 memory B cells exhibiting a CD38hi plasmablastic phenotype in high EBV patients and healthy controls. The proportion of plasmablasts in the high EBV group was highly significantly increased (P , .0001) compared with the healthy controls. (C) Intracellular staining for Ki-67 expression. Naive and memory B cells, sorted by FACS, from a healthy individual and a representative EBV-transformed LCL (included as a positive control) were stained with an anti-Ki-67 antibody (shaded histogram) or isotype control antibody (open histogram) followed by flow cytometric analysis. (D) Ki-67 expression in naive and memory B cells sorted by FACS from 3 allo-HSCT patients with high-level EBV reactivation.

expression (latency I/latency 0).30 Indeed, this notion agrees with our proliferation data showing that around half of the memory B cells were Ki-671. Although there is little information on the expression of EBV genes in the blood of allo-HSCT recipients, previous studies have examined EBV RNA profiling in the context of SOT.17,48-50 Notably, these studies have not identified a common pattern of EBV gene expression associated with reactivation. For example, 1 large-scale study of healthy immunosuppressed cardiothoracic transplant patients revealed multiple patterns of EBV transcription which included LMP2 only, coexpression of LMP1 and LMP2, and coexpression of LMP1, LMP2, and the lytic gene GP350.48 However, around 30% of all posttransplant samples in this study did show evidence of latency III-associated transcripts and this finding correlated with increased viral load. Meanwhile, a smaller study of pediatric liver transplant patients with high chronic EBV loads revealed expression of only LMP2.49 It is unclear to what extent such heterogeneity reflects technical differences in the methods used to detect EBV transcripts in different studies. Comparison between SOT and allo-HSCT may also be further complicated by the fact that SOT patients often exhibit a more chronic

EBV REACTIVATION FOLLOWING ALLO-HSCT

2673

and lower-level viral DNAemia and are less T-cell compromised than allo-HSCT patients. The timing of sample collection in relation to the emergence of EBV reactivation may also be important. These factors may explain the finding of a study by Babcock et al51 which reported that EBV-infected memory cell B cells that accumulate in the blood of healthy immunosuppressed SOT recipients are resting rather than proliferating. Finally, it is interesting to speculate how opportunistic expansion of EBV-transformed B cells leads to the exaggerated numbers of CD271 memory B cells observed in allo-HSCT patients. In immunocompetent individuals, it is proposed that EBV gains access to the long-lived memory B-cell pool by initially infecting naive B cells and then driving them to differentiate through the natural physiologic route of the germinal center.1 However, such a scenario seems unlikely in the context of allo-HSCT patients, given that normal germinal center activity is likely to be disrupted for many months after transplant due to deficiency of CD41 T cells and other supporting cells.52 Notably, microsatellite analysis of CD271 B cells sorted by FACS from patients 6, 9, and 12 confirmed that these cells were all of 100% donor origin (data not shown), and in light of this we propose 2 alternative explanations. In the first, EBV infects mature donor B cells which are transferred in the stem cell graft.53 This mechanism is favored by studies showing that graft B-cell depletion with alemtuzumab (an antiCD52 monoclonal antibody that depletes both T cells and B cells) is associated with a reduced incidence of EBV reactivation compared with antithymocyte globulin–conditioned transplants in which B cells are retained.11,16 The second model proposes that EBV infects newly emerging mature B cells which have differentiated from donor stem cells. This idea is supported by the observation that EBV reactivation is often delayed until 2 to 3 months after transplant, concomitant with the onset of lymphopoiesis. Whether EBV drives the differentiation of emerging naive B cells, either by germinal center transit1 or by inducing a memory phenotype via a GC-independent pathway,54 or through the direct infection of memory B cells,55 remains to be tested.

Acknowledgments The authors thank Roger Bird for help with cell sorting. The authors also thank the patients who contributed to this study. D.M.B. was supported by a Wellcome Trust Clinical Training Fellowship (097439/Z/11/Z). A.B.R., M.R., and A.I.B. were supported by a Cancer Research UK Programme Grant award (C5575/A15032).

Authorship Contribution: D.M.B., R.T., C.S.-L., and A.I.B. designed and performed the experiments; D.M.B., R.T., C.S.-L., M.R., and A.I.B. analyzed and interpreted data; J.C., C.I., B.A., S.N., S.C., and P.M. provided patient samples and data; D.M.B. and A.I.B. wrote the manuscript; and D.M.B., C.P.F., S.C., C.F.C., A.B.R., A.I.B., and M.R. designed and directed the study Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Andrew I. Bell, School for Cancer Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom; e-mail: [email protected].

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. 2674

BURNS et al

BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

References 1. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1): 75-82. 2. Rickinson AB, Long HM, Palendira U, Munz ¨ C, Hislop AD. Cellular immune controls over EpsteinBarr virus infection: new lessons from the clinic and the laboratory. Trends Immunol. 2014;35(4): 159-169. 3. Gottschalk S, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29-44. 4. Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant. 2014;49(2):163-167. 5. Omar H, Hagglund ¨ H, Gustafsson-Jernberg A, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis. 2009;11(5):393-399. 6. Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients. Biol Blood Marrow Transplant. 2011;17(5):591-597. 7. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBVlymphoproliferative disease following T-cell– depleted SCT. Blood. 2001;98(4):972-978. 8. Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant. 2008;42(3): 181-186. 9. Auger S, Orsini M, Ceballos ´ P, et al. Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival. Eur J Haematol. 2014;92(5):421-428. 10. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97(5):1165-1171. 11. Carpenter B, Haque T, Dimopoulou M, et al. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stemcell transplantation. Transplantation. 2010;90(5): 564-570. 12. Gartner ¨ BC, Schafer ¨ H, Marggraff K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol. 2002;40(2):351-358. 13. Meij P, van Esser JW, Niesters HG, et al. Impaired recovery of Epstein-Barr virus (EBV)– specific CD81 T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003;101(11):4290-4297. 14. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr viruslymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99(12):4364-4369. 15. Ahmad I, Cau NV, Kwan J, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation. 2009;87(8):1240-1245.

16. Fox CP, Burns D, Parker AN, et al. EBVassociated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant. 2014; 49(2):280-286. 17. Greijer AE, Stevens SJ, Verkuijlen SA, et al. Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients. Clin Dev Immunol. 2012; 2012:543085. 18. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity. 1998;9(3):395-404. 19. Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV persistence involves strict selection of latently infected B cells. J Immunol. 2000;165(6): 2975-2981. 20. Chaganti S, Heath EM, Bergler W, et al. EpsteinBarr virus colonization of tonsillar and peripheral blood B-cell subsets in primary infection and persistence. Blood. 2009;113(25):6372-6381. 21. Avanzini MA, Locatelli F, Dos Santos C, et al. B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD271 B cells. Exp Hematol. 2005;33(4):480-486. 22. D’Orsogna LJ, Wright MP, Krueger RG, et al. Allogeneic hematopoietic stem cell transplantation recipients have defects of both switched and igm memory B cells. Biol Blood Marrow Transplant. 2009;15(7):795-803. 23. Greinix HT, Pohlreich D, Kouba M, et al. Elevated numbers of immature/transitional CD21B lymphocytes and deficiency of memory CD271 B cells identify patients with active chronic graftversus-host disease. Biol Blood Marrow Transplant. 2008;14(2):208-219. 24. Mensen A, Johrens ¨ K, Anagnostopoulos I, et al. Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT. Blood. 2014;124(6):963-972. 25. Marie-Cardine A, Divay F, Dutot I, et al. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol. 2008;127(1):14-25. 26. Mackall C, Fry T, Gress R, Peggs K, Storek J, Toubert A; Center for International Blood and Marrow Transplant Research (CIBMTR); National Marrow Donor Program (NMDP); European Blood and Marrow Transplant Group (EBMT); American Society of Blood and Marrow Transplantation (ASBMT); Canadian Blood and Marrow Transplant Group (CBMTG); Infectious Disease Society of America (IDSA); Society for Healthcare Epidemiology of America (SHEA); Association of Medical Microbiology and Infectious Diseases Canada (AMMI); Centers for Disease Control and Prevention (CDC). Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant. 2009;44(8):457-462. 27. Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol. 2008;30(4):425-437. 28. Geddes M, Storek J. Immune reconstitution following hematopoietic stem-cell transplantation. Best Pract Res Clin Haematol. 2007;20(2): 329-348. 29. Bemark M, Holmqvist J, Abrahamsson J, Mellgren K. Translational Mini-Review Series on B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation - revelation

of B cell developmental pathways and lineage phenotypes. Clin Exp Immunol. 2012;167(1):15-25. 30. Rowe M, Kelly GL, Bell AI, Rickinson AB. Burkitt’s lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol. 2009;19(6):377-388. 31. Krenger W, Blazar BR, Hollander ¨ GA. Thymic T-cell development in allogeneic stem cell transplantation. Blood. 2011;117(25):6768-6776. 32. D’Aveni M, A¨ıssi-Rothe´ L, Venard V, et al. The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2011;24(4):224-232. 33. Annels NE, Kalpoe JS, Bredius RG, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis. 2006;42(12):1743-1748. 34. Chakrabarti S, Milligan DW, Pillay D, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-celldepleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood. 2003; 102(3):839-842. 35. Storek J, Witherspoon RP, Storb R. Reconstitution of membrane IgD- (mIgD-) B cells after marrow transplantation lags behind the reconstitution of mIgD1 B cells. Blood. 1997; 89(1):350-351. 36. Klein U, Rajewsky K, Kuppers ¨ R. Human immunoglobulin (Ig)M1IgD1 peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med. 1998; 188(9):1679-1689. 37. Fox CP, Shannon-Lowe C, Rowe M. Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. Herpesviridae. 2011;2:8. 38. Calattini S, Sereti I, Scheinberg P, Kimura H, Childs RW, Cohen JI. Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using ImmunoFISH. Blood. 2010;116(22):4546-4559. 39. Khan G, Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Is EBV persistence in vivo a model for B cell homeostasis? Immunity. 1996; 5(2):173-179. 40. Hoshino Y, Katano H, Zou P, et al. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol. 2009;83(22): 11857-11861. 41. Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB. Three restricted forms of EpsteinBarr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci USA. 2006;103(40):14935-14940. 42. Shannon-Lowe C, Adland E, Bell AI, Delecluse HJ, Rickinson AB, Rowe M. Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification. J Virol. 2009;83(15):7749-7760. 43. Sternas ˚ L, Middleton T, Sugden B. The average number of molecules of Epstein-Barr nuclear antigen 1 per cell does not correlate with the average number of Epstein-Barr virus (EBV) DNA molecules per cell among different clones of EBVimmortalized cells. J Virol. 1990;64(5):2407-2410.

From www.bloodjournal.org by guest on September 11, 2016. For personal use only. BLOOD, 17 DECEMBER 2015 x VOLUME 126, NUMBER 25

44. Rose C, Green M, Webber S, et al. Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization. J Clin Microbiol. 2002;40(7):2533-2544. 45. Speck SH, Strominger JL. Transcription of Epstein-Barr virus in latently infected growth transformed lymphocytes. In: Klein G, ed. Advances in Viral Oncology. Vol. 8. New York, NY: Raven Press; 1989:133-150. 46. Alfieri C, Birkenbach M, Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology. 1991;181(2):595-608. 47. Allday MJ, Crawford DH, Griffin BE. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol. 1989;70(Pt 7): 1755-1764. 48. Hopwood PA, Brooks L, Parratt R, et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression

EBV REACTIVATION FOLLOWING ALLO-HSCT

in healthy immunosuppressed transplant recipients [Transplantation. 2003;75(1):168]. Transplantation. 2002;74(2):194-202. 49. Gotoh K, Ito Y, Ohta R, et al. Immunologic and virologic analyses in pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. J Infect Dis. 2010;202(3):461-469. 50. Qu L, Green M, Webber S, Reyes J, Ellis D, Rowe D. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis. 2000;182(4):1013-1021. 51. Babcock GJ, Decker LL, Freeman RB, ThorleyLawson DA. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med. 1999; 190(4):567-576. 52. Sale GE, Alavaikko M, Schaefers KM, Mahan CT. Abnormal CD4:CD8 ratios and delayed germinal

2675

center reconstitution in lymph nodes of human graft recipients with graft-versus-host disease (GVHD): an immunohistological study. Exp Hematol. 1992;20(8):1017-1021. 53. Lausen BF, Hougs L, Schejbel L, Heilmann C, Barington T. Human memory B cells transferred by allogenic bone marrow transplantation contribute significantly to the antibody repertoire of the recipient. J Immunol. 2004;172(5): 3305-3318. 54. Heath E, Begue-Pastor N, Chaganti S, et al. Epstein-Barr virus infection of na¨ıve B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology. PLoS Pathog. 2012;8(5):e1002697. 55. Kurth J, Spieker T, Wustrow J, et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity. 2000;13(4): 485-495.

From www.bloodjournal.org by guest on September 11, 2016. For personal use only.

2015 126: 2665-2675 doi:10.1182/blood-2015-08-665000 originally published online October 8, 2015

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event David M. Burns, Rose Tierney, Claire Shannon-Lowe, Jo Croudace, Charlotte Inman, Ben Abbotts, Sandeep Nagra, Christopher P. Fox, Sridhar Chaganti, Charles F. Craddock, Paul Moss, Alan B. Rickinson, Martin Rowe and Andrew I. Bell

Updated information and services can be found at: http://www.bloodjournal.org/content/126/25/2665.full.html Articles on similar topics can be found in the following Blood collections Free Research Articles (4041 articles) Immunobiology (5415 articles) Plenary Papers (483 articles) Transplantation (2160 articles) Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.

Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.

Allogeneic stem cell transplantation (allo-HSCT) provides a unique opportunity to track Epstein-Barr virus (EBV) infection in the context of the recon...
1KB Sizes 0 Downloads 14 Views